Most relevant data are within the paper and its Supporting Information files. Raw sequencing data is available at Open Science Framework (DOI [10.17605/OSF.IO/B5JGS](https://doi.org/10.17605/OSF.IO/B5JGS)).

Introduction {#sec006}
============

Neurogenetic disorders are a frequent reason for medical consultation in neurology services. Clinical variability and genetic heterogeneity are a hallmark of these diseases. Their diagnostic approach requires extensive clinical, radiological and genetic evaluations. Moreover, many of these procedures are invasive and costly. However, despite the use of considerable time and resources, the diagnostic yield in this field has been disappointingly low. This etiologic search has been called a "diagnostic odyssey" for many families \[[@pone.0191228.ref001]\].

Whole Exome Sequencing (WES) has proved to be a valuable tool in medical genetics, for diagnostic and gene discovery purposes \[[@pone.0191228.ref002]--[@pone.0191228.ref004]\]. Although a diagnostic yield of about 30% in neurogenetic disorders can be extrapolated from the results of large series that have included other medical conditions as well \[[@pone.0191228.ref005]\], specific reports assessing its utility in a setting such as ours---a *neurogeneticist led* academic group serving in a low-income country---are rare. Therefore, there is still a necessity to assess its clinical utility and the feasibility of its implementation for neurogenetic diagnostic practice in less economic favorable locations where rational and effective use of resources is both an obligation and an opportunity for reducing inequalities \[[@pone.0191228.ref006], [@pone.0191228.ref007]\].

We are reporting here on our first 40 consecutive cases which were selected from our research-based laboratory for WES. We demonstrated the clinical utility of WES and the potential cost-effectiveness of WES as a single test by examining the number and types of tests that were performed prior to WES that add to the cost of diagnostic workups.

Materials and methods {#sec007}
=====================

Clinical samples {#sec008}
----------------

We included a consecutive series of 40 patients selected for WES from a Neurogenetic Clinic of a tertiary Hospital in Argentina. These patients were considered candidates for genomic studies according to the presence of typical findings of known neurogenetic diseases and/or hints of monogenic etiology such as familial aggregation or chronic and progressive course. We recorded perinatal and family history, likely inheritance model/s, disease progression characteristics, comorbidities, and studies performed before WES from each patient of our cohort. The diverse clinical features of this cohort are summarized in [Table 1](#pone.0191228.t001){ref-type="table"}. Written informed Consent for WES was obtained from the patients and/or their family. The informed consent included the option to receive or not incidental findings according to ACMG recommendations. Internal review board (IRB) approval was obtained at Hospital JM Ramos Mejia. All methods were performed in accordance with the relevant guidelines and regulations.

10.1371/journal.pone.0191228.t001

###### Demographic characteristics and clinical features of patients selected for WES ([\*](#t001fn001){ref-type="table-fn"}).

![](pone.0191228.t001){#pone.0191228.t001g}

  CASE ID   AGE OF ONSET   AGE AT TESTING   PRIMARY DISEASE CLASSIFICATION          CLINICAL PRESENTATION
  --------- -------------- ---------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------
  1         1              28               \-                                      Mental retardation, autism, epilepsy, dystonia
  2         5              9                Epilepsy with Variable Foci             Epilepsy
  3         1              5                Dravet Syndrome                         Epilepsy, cognitive impairment
  4         9              17               Hemiplegic Migraine                     Episodic migraine, hemiplegia
  5         14             24               Sporadic ataxia                         Ataxia, myoclonus, cognitive impairment, cerebellar atrophy on MRI
  6         9              24               Spastic Paraplegia Plus                 Paraplegia, mental retardation, thinning of the corpus callosum on MRI, peripheral neuropathy
  7         4              23               \-                                      Generalized dystonia, chorea, cognitive impairment
  8         2              5                Epileptic encephalopathy                Ataxia, absence epilepsy, neurodevelopmental delay
  9         8              50               Myopathy                                Very mild muscle weakness, hyperCKemia
  10        1              11               Epileptic encephalopathy                Autism, hyperactivity, epilepsy
  11        6              11               Ataxia + oculomotor apraxia             Ataxia, chorea, tremor, oculomotor apraxia
  12        16             23               Leukodystrophy                          leukodystrophy on MRIs + cognitive impairment Ataxia + pyramidal syndrome + abnormal eye movements
  13        55             70               Sporadic ataxia                         Ataxia
  14        1              4                Leigh syndrome                          Developmental delay, refractory epileptic encephalopathy, MRI signal abnormalities in the basal ganglia
  15        11             22               Mitochondrial Disorder                  Muscle fatigue
  16        1              5                Chain respiratory disorder              Developmental delay, recurrent vomiting
  17        29             54               Sporadic ataxia                         Ataxia, pyramidal.
  18        5              15               Ataxia                                  Ataxia, neuropathy, cerebellar atrophy
  19        2              12               \-                                      Developmental Disorder, speech impairment, polyneuropathy
  20        42             53               Sporadic ataxia                         Ataxia, cerebellar atrophy
  21        3              11               Epileptic encephalopathy                Partial seizures, ataxia
  22        Neonatal       3                Neonatal adrenoleukodystrophy           Hepatic dysfunction, hypotonia, white matter lesions on MRI
  23        Neonatal       3                Encephalopathy                          Mental delay, physical growth retardation, diarrhea, vomiting and increased lactic acid
  24        Neonatal       9                Encephalopathy                          Developmental delay, seizures, muscular weakness, dystonia. Fragmentary hypo myelination on MRI
  25        30             52               Episodic ataxia                         Episodic ataxia
  26        12             23               Leukodystrophy                          Ataxia, cognitive impairment, abnormal ocular movements. Symmetric hypo myelination on MRI
  27        27             33               Rhabdomyolysis                          Rhabdomyolysis, muscular fatigue
  28        6m             5                Mitochondrial                           Developmental delay, epilepsy, dystonia, ragged red fibers on muscular biopsy
  29        3              32               Myopathy                                Proximal muscular weakness, muscular atrophy
  30        Neonatal       8                Congenital disorder of Glycosylation    Microcephaly, seizures, muscular weakness
  31        Neonatal       10               Polymicrogyria                          Seizures, polymicrogyria on MRI
  32        2              8                \-                                      Speech impairment, developmental delay
  33        18m            31               Spastic quadriplegia                    Quadriplegia, pyramidal dysfunction, fasciculation, muscular atrophy
  34        50             58               Ataxia / Dementia                       Progressive multidomain cognitive impairment, ataxia
  35        6m             5                Myopathy                                Developmental delay, hypotonia, muscular weakness
  36        8              19               Dystonia                                Generalized dystonia
  37        2              16               Optic Neuropathy                        Progressive visual loss
  38        41             53               Sensory Ataxia                          Ataxia, distal hypoesthesia
  39        6              17               NBIA                                    Dystonia, tremor
  40        46             56               Sub-acute Dementia-Movement Disorders   Behavioral disorders, tremor, bradykinesia

\*36 patients were selected for WES based on the presence of a well-defined clinical syndrome; the first-tier analysis was done by investigating a panel of known disease genes known to be associated with the respective condition. The rest represents complex phenotypes with overlapping neurological features. The mean age at WES was 23, ranging from 3--70 years. (Age at testing column)

The mean time between the disease onset and WES was 11.5 years (range 3--42).

Whole exome sequencing and sanger confirmation {#sec009}
----------------------------------------------

Genomic DNA was isolated from blood samples of each subject with the use of commercial kits. DNA sequencing libraries were constructed mostly by chemical fragmentation using commercial preparation kits. Exomes were enriched using different systems, being the vast majority of our cases processed with SureSelect Human All Exon v4 Kits (Agilent Technologies, Santa Clara, CA, USA). NGS sequencing runs were made in Illumina HiSeq 2500 systems as an outsourced service from Macrogen Inc (Korea) obtaining an average sequence coverage of more than 70X, with more than 97% of the target bases having at least 10X coverage. All standardized procedures were performed according to manufacturer's instructions that have been widely mentioned in the literature \[[@pone.0191228.ref008], [@pone.0191228.ref009]\]. Clinically relevant variants, from proband and parental samples (whenever available), were confirmed by Sanger sequencing.

Data analysis and annotation {#sec010}
----------------------------

Sequence data in FastQ format were aligned to the human reference genome (GRCh37) using the Burrows-Wheeler Alignment Tool (BWA-MEM) \[[@pone.0191228.ref010]\]. Variants Calls were generated using GATK haplotype caller following the so called *best practices* \[[@pone.0191228.ref011]\]. The output vcf file was annotated at various levels using Annovar \[[@pone.0191228.ref012]\] ([S1A Fig](#pone.0191228.s002){ref-type="supplementary-material"}). Variants were prioritized according to inheritance model, population frequency, molecular function and effects of mutations, reported clinical effect, and optionally according to a list of genes associated with the disease under study. In that sense two in-house protocols were defined. One "molecular hypothesis free", for patients presenting complex phenotypes without candidate genes. Another "molecular hypothesis targeted" for patients that shows a defined clinical syndrome with available candidate genes. ([S1B Fig](#pone.0191228.s002){ref-type="supplementary-material"}). Classification of variants followed previously published schemes \[[@pone.0191228.ref013]\] updated with recent recommendations and guidelines by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology \[[@pone.0191228.ref014]\]. Joining variant level and clinical features information, we classified each WES study as **positive** if *a pathogenic/likely pathogenic mutation in known disease gene was identified with positive phenotypic and inheritance overlap*; **undetermined** if *a pathogenic/likely pathogenic mutation in a putative candidate gene was identified with positive phenotypic and inheritance overlap* or *only one pathogenic/likely pathogenic mutation was identified with positive phenotypic overlap in a recessive disorder* and **negative** *in the rest of the cases*. We paid special attention to reviews of previous work done in cases studied before the 2015 update, reanalyzing them according to the new schema. Details for each novel variant are presented in [S1 Table](#pone.0191228.s001){ref-type="supplementary-material"}.

Incidental findings were informed according to ACMG recommendations. Counseling to patients was performed by trained professionals.

Results {#sec011}
=======

WES proved to be an effective, cost- and time-saving diagnostic approach in our setting. Sixteen WES satisfied criteria for a full molecular diagnosis ([Table 2](#pone.0191228.t002){ref-type="table"} and [S1 Table](#pone.0191228.s001){ref-type="supplementary-material"}), thus the overall diagnostic yield for WES in our series was 40% ([S2 Fig](#pone.0191228.s003){ref-type="supplementary-material"}, Yield). Among them, two WES were reclassified from original undetermined and negative categories after subsequent reanalysis identified pathogenic variants in genes not associated with human disorders at the time of original reports. A diverse group of neurological disorders were represented in the positive patients ([Table 2](#pone.0191228.t002){ref-type="table"}). The average age at the time of WES was 23 (3--70). The mean time elapsed from symptom onset to WES was 11 years (range 3--42). The positive group included 9 patients with autosomal dominant disease and 7 with autosomal recessive disease. Different mutation types were observed in this cohort. Noteworthy, 56% of the mutations were novel, according to ExAC v3 database \[[@pone.0191228.ref009]\] ([Fig 1](#pone.0191228.g001){ref-type="fig"}). Although almost all of the molecular diagnoses were in nuclear genes, mitochondrial genome sequencing included in the WES test yielded one diagnosis (one individual with a missense mutation in MT-T8993G.

10.1371/journal.pone.0191228.t002

###### Summary of patients with established molecular diagnosis by WES.

![](pone.0191228.t002){#pone.0191228.t002g}

  ------------------------------------------------ ----------- ------------------------------------------------------------------------------------------------------------------- ---------------- -------------------------------------- --------------------------------------------------------------------------------- ----------------------------- ---------------------------- -------------------------------------------------------------
  **CASE ID**                                      **GENE**    **PHENOTYPE**                                                                                                       **OMIM Entry**   **INHERITANCE/ SEGREGATION**           **MUTATION(S)**                                                                   **LITERATURE**                **TYPE OF MUTATION**         **ALTERED MANAGEMENT**
  1 [(\*)](#t002fn003){ref-type="table-fn"}        *GRIK2*     Mental Retardation, autism, epilepsy, dystonia                                                                      611092           Recessive (Both parents inheritance)   NM_021956.4:c592C\>T; p.R198X Hom                                                 (Motazacker MM et al. 2007)   *nonsense*                   
  2                                                *DEPDC5*    Epilepsy with Variable Foci                                                                                         604364           Dominant (paternal inheritance)        NM_001242896:c.4718T\>C;p.L1573P                                                  (Baulac et al. 2014)          *missense*                   
  4                                                *CACNA1A*   Hemiplegic Migraine                                                                                                 141500           Sporadic (De novo)                     NM_000068:c.3675C\>A; p.F1225L                                                    (Riant et al. 2010)           *missense*                   
  5 [(\*\*)](#t002fn004){ref-type="table-fn"}      *STUB1*     Sporadic Ataxia                                                                                                     607207           Sporadic (Both parents inheritance)    NM_005861.2:c.612+1 G\> C; p.? NM_005861.2:c.823C\>G;L275V                        (Shi et al. 2014)             *splicing/missense*          Endocrine monitoring to evaluate appearance of hypogonadism
  6                                                *SPG11*     Paraplegia, mental retardation, thinning of the corpus callosum peripheral neuropathy                               604360           Sporadic (Both parents inheritance)    NM_025137:c.6763insA; p.L2255Hfsx85 NM_025137:6726A\>T; p.Q2242H;                 (Stevanin et al. 2007)        *Frameshift/ missense*       L-Dopa Trial
  8                                                *KCNA2*     Ataxia, early absence epilepsy, neurodevelopmental delay                                                            616366           Sporadic (De novo)                     NM_001204269::c.G890A:p.R297Q (a)                                                 (Syrbe et al. 2015)           *missense*                   Acetazolamide and Fampridine Trial
  9                                                *DMD*       Myopathy with very mild muscle weakness, hyperCKemia                                                                300377           Sporadic                               NM_004006.2:c.1149+1C\>A (b) Het                                                  (Carsana et al. 2010)         *splicing*                   Avoid Statins
  11                                               *APTX*      Ataxia, chorea, tremor, oculomotor apraxia                                                                          208920           Recessive (Both parents inheritance)   NM_175069.1:c.879G\>A; p.W293X (c) Hom                                            (Shimazaki et al. 2002)       *nonsense*                   Ubiquinone Trial
  21                                               *PCDH19*    Epileptic encephalopathy with partial seizures and ataxia                                                           300088           Sporadic (paternal inheritance)        NM_001184880:exon1:c.T1151G:p.V384G                                               (Hynes et al. 2010)           *nonsense*                   
  22                                               *PEX12*     Neonatal adrenoleukodystrophy with hepatic dysfunction, hypotonia, white matter lesions on MRI                      266510           Sporadic (Both parents inheritance)    NM_000286:c.733_734insGCC;p.L245Cfsx19 (d) NM_000286:c.533_535del:p.Q178del (e)   (Gootjes et al. 2004)         *Frameshift/nonframeshift*   
  26                                               *POLR3A*    Leukodystrophy with ataxia, cognitive impairment, abnormal ocular movements and symmetric hypo myelination on MRI   607694           Recessive (Both parents inheritance)   NM_007055.3:c.3781G\>A; p.Q1261KNM_007055.3:c.3014G\>A;p.R1005H (f)               (Wolf et al. 2014)            *Missense/missense*          
  28                                               *MT-ATP6*   Mitochondrial disease with ddevelopmental delay, epilepsy, dystonia, ragged red fibers on muscular biopsy           551500           Mitochondrial                          m.T8993G (g)                                                                      (Holt et al. 1990)            *missense*                   Avoid drugs with mitochondrial toxicity
  29                                               *SGCG*      Myopathy with proximal muscular weakness, muscular atrophy                                                          608896           Sporadic (both parents inheritance)    NM_000231: c.521delT:p.F175LfsX20 (h) Hom                                         (Lasa et al. 1998)            *frameshift*                 
  30                                               *GNAO1*     Glycosylation congenital disorder with microcephaly, seizures, muscular weakness                                    615473           Sporadic (De novo)                     NM_020988: c.709G\>A:p.Q237K                                                      (Nakamura et al. 2013)        *missense*                   
  33                                               *ALS2*      Spastic quadriplegia, pyramidal dysfunction, fasciculation, muscular atrophy                                        607225           Sporadic (both parents inheritance)    NM_020919: c.T2531A: p.L844H Hom                                                  (Eymard-Pierre et al. 2006)   *missense*                   
  40 [(\*\*\*)](#t002fn005){ref-type="table-fn"}   *ATP7B*     Sub-acute Dementia with movement Disorders                                                                          277900           Recessive (Both parents inheritance)   NM_000053: c.2165T\>A: p.L722Q NM_000053: c.3704G\>A: p.G235N                     (Takeshita et al. 2002)       *Missense*/*missense*        Treatment with Penicilamine
  **CASE ID**                                      **GENE**    **PHENOTYPE**                                                                                                       **OMIM Entry**   **INHERITANCE/ SEGREGATION**           **MUTATION(S)**                                                                   **LITERATURE**                **TYPE OF MUTATION**         **ALTERED MANAGEMENT**
  1 [(\*)](#t002fn003){ref-type="table-fn"}        *GRIK2*     Mental Retardation, autism, epilepsy, dystonia                                                                      611092           Recessive (Both parents inheritance)   NM_021956.4:c592C\>T; p.R198X Hom                                                 (Motazacker MM et al. 2007)   *nonsense*                   
  2                                                *DEPDC5*    Epilepsy with Variable Foci                                                                                         604364           Dominant (paternal inheritance)        NM_001242896:c.4718T\>C;p.L1573P                                                  (Baulac et al. 2014)          *missense*                   
  4                                                *CACNA1A*   Hemiplegic Migraine                                                                                                 141500           Sporadic (De novo)                     NM_000068:c.3675C\>A; p.F1225L                                                    (Riant et al. 2010)           *missense*                   
  5 [(\*\*)](#t002fn004){ref-type="table-fn"}      *STUB1*     Sporadic Ataxia                                                                                                     607207           Sporadic (Both parents inheritance)    NM_005861.2:c.612+1 G\> C; p.? NM_005861.2:c.823C\>G;L275V                        (Shi et al. 2014)             *splicing/missense*          Endocrine monitoring to evaluate appearance of hypogonadism
  6                                                *SPG11*     Paraplegia, mental retardation, thinning of the corpus callosum peripheral neuropathy                               604360           Sporadic (Both parents inheritance)    NM_025137:c.6763insA; p.L2255Hfsx85 NM_025137:6726A\>T; p.Q2242H;                 (Stevanin et al. 2007)        *Frameshift/ missense*       L-Dopa Trial
  8                                                *KCNA2*     Ataxia, early absence epilepsy, neurodevelopmental delay                                                            616366           Sporadic (De novo)                     NM_001204269::c.G890A:p.R297Q (a)                                                 (Syrbe et al. 2015)           *missense*                   Acetazolamide and Fampridine Trial
  9                                                *DMD*       Myopathy with very mild muscle weakness, hyperCKemia                                                                300377           Sporadic                               NM_004006.2:c.1149+1C\>A (b) Het                                                  (Carsana et al. 2010)         *splicing*                   Avoid Statins
  11                                               *APTX*      Ataxia, chorea, tremor, oculomotor apraxia                                                                          208920           Recessive (Both parents inheritance)   NM_175069.1:c.879G\>A; p.W293X (c) Hom                                            (Shimazaki et al. 2002)       *nonsense*                   Ubiquinone Trial
  21                                               *PCDH19*    Epileptic encephalopathy with partial seizures and ataxia                                                           300088           Sporadic (paternal inheritance)        NM_001184880:exon1:c.T1151G:p.V384G                                               (Hynes et al. 2010)           *nonsense*                   
  22                                               *PEX12*     Neonatal adrenoleukodystrophy with hepatic dysfunction, hypotonia, white matter lesions on MRI                      266510           Sporadic (Both parents inheritance)    NM_000286:c.733_734insGCC;p.L245Cfsx19 (d) NM_000286:c.533_535del:p.Q178del (e)   (Gootjes et al. 2004)         *Frameshift/nonframeshift*   
  26                                               *POLR3A*    Leukodystrophy with ataxia, cognitive impairment, abnormal ocular movements and symmetric hypo myelination on MRI   607694           Recessive (Both parents inheritance)   NM_007055.3:c.3781G\>A; p.Q1261KNM_007055.3:c.3014G\>A;p.R1005H (f)               (Wolf et al. 2014)            *Missense/missense*          
  28                                               *MT-ATP6*   Mitochondrial disease with ddevelopmental delay, epilepsy, dystonia, ragged red fibers on muscular biopsy           551500           Mitochondrial                          m.T8993G (g)                                                                      (Holt et al. 1990)            *missense*                   Avoid drugs with mitochondrial toxicity
  29                                               *SGCG*      Myopathy with proximal muscular weakness, muscular atrophy                                                          608896           Sporadic (both parents inheritance)    NM_000231: c.521delT:p.F175LfsX20 (h) Hom                                         (Lasa et al. 1998)            *frameshift*                 
  30                                               *GNAO1*     Glycosylation congenital disorder with microcephaly, seizures, muscular weakness                                    615473           Sporadic (De novo)                     NM_020988: c.709G\>A:p.Q237K                                                      (Nakamura et al. 2013)        *missense*                   
  33                                               *ALS2*      Spastic quadriplegia, pyramidal dysfunction, fasciculation, muscular atrophy                                        607225           Sporadic (both parents inheritance)    NM_020919: c.T2531A: p.L844H Hom                                                  (Eymard-Pierre et al. 2006)   *missense*                   
  40 [(\*\*\*)](#t002fn005){ref-type="table-fn"}   *ATP7B*     Sub-acute Dementia with movement Disorders                                                                          277900           Recessive (Both parents inheritance)   NM_000053: c.2165T\>A: p.L722Q NM_000053: c.3704G\>A: p.G235N                     (Takeshita et al. 2002)       *Missense*/*missense*        Treatment with Penicilamine
  ------------------------------------------------ ----------- ------------------------------------------------------------------------------------------------------------------- ---------------- -------------------------------------- --------------------------------------------------------------------------------- ----------------------------- ---------------------------- -------------------------------------------------------------

Dominant inheritance was defined by the presence of an affected parent and recessive inheritance defined by unaffected parents and affected siblings

\(a\) ClinVar \#190328; (b) UMD-DMD France Mutation Database Records 14050 and 18392; (c) ClinVar \#4431; (d) and (e) cited in Mol Genet Metab. 2004 Nov;83(3):252--63; (f) ClinVar \#31149; (g) ClinVar \#9461; (h) ClinVar \#2004;

(\*) Further details were published in Clin Genet. 2015 Mar;87(3):293--5. doi: [10.1111/cge.12423](https://doi.org/10.1111/cge.12423).

(\*\*) Further details were previously published in Neurology. 2014 Jul 15;83(3):287--8.

(\*\*\*) Further details were previously published in Parkinsonism Relat Disord. 2015 Nov;21(11):1375--7.

![Location and impact of novel variants identified by this study.](pone.0191228.g001){#pone.0191228.g001}

As we mention in methods, a WES study is considered *positive* if pathogenic or likely pathogenic variants correspond to the phenotype and the mode of inheritance. We must recognize that only in case 33, this criterion is not strictly accomplished because the identified variant in *ALS2* must be considered of unknown significance according to last ACMG criteria. However, we discussed this situation with the referring physician and the patient's family and decided to consider the *ALS2* variant likely causing the disease, despite acknowledging a higher uncertainty in diagnostic terms. According to this clinical decision, we included this case as a positive one into this work.

WES were defined as undetermined in two cases (5%). In one of them, we were able to identify only one pathogenic variant (NM_018082.5:c.1568T\>A; p.V523Q) in *POLR3B* in a patient showing clinical features consistent with autosomal recessive *POLR3*-related disorders \[[@pone.0191228.ref015]\]. We hypothesize that the second missing allele is a large deletion/insertion or a deep intronic mutation. This case highlights current limitations of WES. In case 17, we found a heterozygous likely pathogenic variant (NM_030954.3:c.668C\>A; p.A223N) in *RNF170* gene. This gene was reported as a cause of sensory ataxia \[[@pone.0191228.ref016]\]. The patient's phenotype corresponds to pure cerebellar ataxia.

[Table 2](#pone.0191228.t002){ref-type="table"} shows a summary of the impact that a definitive diagnosis obtained from WES had on our patients. The information obtained by means of WES ended the diagnostic odysseys, led to therapeutic trials in some cases and improved genetic counselling processes with more precise information.

As an exploratory approach to a monetary cost-analysis of WES in neurogenetic diseases, we recorded the number and type of complementary tests done by our patients before WES. The average cost of the "expendable" diagnostic workup prior to WES was USD 1646 (USD 1439 to 1853), which is 60% higher than WES cost in our center (USD 1000). [Table 3](#pone.0191228.t003){ref-type="table"} shows that several genetic and non-genetic assays considered unnecessary (e.g. repetitive neuroimages and non-genetic assays) and/or evitable (e.g. recurrent outpatients visits and single-gene testing) were performed in almost all of our patients. This often-unnecessary repetition of complementary studies might be a consequence of the extension in time of the so-called *diagnostic odyssey* (see before results about time at WES since symptom onset). A more conservative analysis that added up WES cost and stratified the cohort into solved and unsolved cases showed differences too. The average cost of the diagnostic work up (including WES, expendable and non-expendable procedures) in solved cases was USD 4572 (USD 4302 to 4842), whereas in unsolved cases was USD 4514 (USD 4289 to 4739). Avoiding expendable procedures, by means of WES, could reduce diagnostic work up expenses in about 39% (USD 2792; 95% CI, USD 2634--2950).

10.1371/journal.pone.0191228.t003

###### Summary of procedures[\*](#t003fn001){ref-type="table-fn"} and visits[\*](#t003fn001){ref-type="table-fn"} performed during the *Diagnostic Odysseys*.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case id   CT      MRI   EMG   Biochemical genetics   Muscle biopsies   CSF   Prior Genetic Testing\      Total number of unnecessary previous studies   Number of extra specialized outpatient's visits   Total estimated expendable\   Total diagnostic procedures (non-expendable) (USD)
                                                                               (all single gene testing)                                                                                                    cost (USD)                    
  --------- ------- ----- ----- ---------------------- ----------------- ----- --------------------------- ---------------------------------------------- ------------------------------------------------- ----------------------------- ----------------------------------------------------
  1         1       2                                                                                      3                                              5                                                 2149                          2801

  2                                                                                                        0                                              4                                                 1000                          2942

  3         **1**                                                                                          1                                              3                                                 935                           3079

  4                 2                                                                                      2                                              6                                                 2214                          1957

  5         1       2     1                                                    3                           7                                              4                                                 2913                          3171

  6                 1     1                                                                                2                                              5                                                 1792                          2730

  7         1       2                                                                                      3                                              2                                                 1399                          3137

  8                                                                                                        0                                              4                                                 1000                          3194

  9                       1                                                                                1                                              6                                                 1614                          2564

  10                1                                                                                      1                                              8                                                 2357                          2237

  11                1                                                                                      1                                              4                                                 1357                          2637

  12        1       2     1                                                                                4                                              6                                                 2513                          1641

  13        1       1                                                          1                           3                                              5                                                 842                           4941

  14                1                                                                                      1                                              4                                                 1357                          2871

  15                      1                                                                                1                                              3                                                 814                           3678

  16                                                                                                       0                                              4                                                 1000                          3478

  17                2                                                          1                           3                                              6                                                 2514                          3357

  18                2                                                          1                           3                                              5                                                 2264                          3221

  19                1                                                                                      1                                              3                                                 1107                          3101

  20                2                                                          1                           3                                              2                                                 1157                          3314

  21                1                                                                                      1                                              4                                                 1357                          2837

  22                2                                                                                      2                                              6                                                 2214                          2757

  23                                                                                                       0                                              5                                                 1250                          3214

  24                                                                                                       0                                              4                                                 1000                          3364

  25        1       2                                                                                      3                                              5                                                 2149                          2250

  26                1                                                                                      1                                              6                                                 1857                          2457

  27                      2                                                                                2                                              7                                                 1978                          2443

  28                                                                                                       0                                              6                                                 1500                          3178

  29                      2                            1                                                   3                                              3                                                 1585                          2928

  30                1                                                                                      1                                              6                                                 1857                          2478

  31                1                                                                                      1                                              4                                                 1357                          2757

  32        1       1                                                                                      2                                              7                                                 2292                          2387

  33                1     3                                                                                4                                              6                                                 2199                          3000

  34                1                                                                                      1                                              4                                                 1114                          3000

  35                      1                                                                                1                                              2                                                 614                           3278

  36                1                                                                                      2                                              4                                                 1357                          2757

  37                2                                                                                      2                                              6                                                 2214                          2100

  38                1                                                                                      3                                              4                                                 1828                          2951

  39        2       1                                                                                      3                                              3                                                 1977                          2407

  40        1       1                                                    1                                 3                                              5                                                 1872                          3044
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Only repetitive procedures and visits were considered unnecessary. Thus, only them were summed up for the costs of diagnostic odysseys.

Discussion {#sec012}
==========

Applying WES to a representative sample of 40 patients suffering from neurogenetic diseases, we obtained an etiologic diagnostic yield of 40%. Furthermore, we were able to expand the phenotypic spectrum of known genes and identify new pathogenic variants in other genes. Two cases were illustrative of common themes in medical genomics \[[@pone.0191228.ref017], [@pone.0191228.ref018]\]. A non-sense mutation in *GRIK2* caused a more complex phenotype than it was previously recognized for this gene. This gene encodes a glutamate receptor and was previously reported once in members of a consanguineous family segregating intellectual disability \[[@pone.0191228.ref019]\]. Our patient also presented with intellectual disability, epilepsy, dystonia, and behavioral problems of the autism spectrum \[[@pone.0191228.ref020]\]. Thus, we were able to extend the phenotypic spectrum associated with this gene. We also emphasize the finding of a mutation in *KCNA2* in a patient with early onset epilepsy and ataxia. This variant was identified after periodic reanalysis of previously non-diagnostic WES. Mutations in *KCNA2* were recently recognized as the cause of epileptic encephalopathies and early onset ataxia \[[@pone.0191228.ref021]\]. This information was unknown at the moment of the initial analysis, however, being available when this WES was reassessed, it led us to reinterpret this case. Recent reports have shown that systematic re-analysis of unsolved WES data lead to about 10% additional diagnoses \[[@pone.0191228.ref022]\].

Our preliminary cost-analysis lend support to the assertion made by others that WES is more cost-effective than other molecular diagnostic approaches based on single- or panel- gene analysis \[[@pone.0191228.ref002], [@pone.0191228.ref003]\]. However, our estimates ought to be interpreted with caution. The retrospective design precludes us to avoid biases during the classification of previous procedures as unnecessary or evitable. We acknowledge that some of them could certainly be useful for WES interpretation and should not be considered a complete cost to be saved by WES. Nevertheless, our findings are similar to other formal analyses in this subject \[[@pone.0191228.ref023]\], where an early implementation of WES in the diagnostic trajectory of suspected genetic conditions proves to be cost-effective by means of a reduction in the number of procedures and specialist visits \[[@pone.0191228.ref024]\]. Moreover, there are other *diagnostic odysseys* costs that are harder to represent in monetary terms but are not less important, such as time lost to the patient and family and quality of life decrement because of this loss. They deserve other type of formal economic studies that could even show more advantages for the use of WES in the diagnostic approach of complex diseases such as neurogenetic disorders.

The diagnostic yield in less restrictive adult and pediatric populations series ranged from 17 to 30% \[[@pone.0191228.ref004], [@pone.0191228.ref025]\]. Groups that included only patients showing phenotypes involving the nervous system reported higher diagnostic yields \[[@pone.0191228.ref026]--[@pone.0191228.ref028]\]. Our results are comparable with these experiences and highlight the advantages of working as a personalized research group where phenotypic and genotypic information can be thoughtfully assessed in contrast to commercial diagnostic laboratories that only have access to focused, heterogeneous and often less informative clinical phenotypic reports filled by the external ordering physician. Although undirected next generation sequencing tests such as WES have proved powerful and useful in the diagnosis of several genetic conditions, a targeted approach based on multi-genic panels or even single-gene assays is still justified for patients presenting with well-defined phenotypes where a higher diagnostic yield might be expected because of better coverage and more favorable cost implications \[[@pone.0191228.ref029]\]. However, WES have the advantage over more focused approaches, when a more comprehensive solution is needed in those patients suffering from genetically and phenotypically heterogeneous conditions \[[@pone.0191228.ref030], [@pone.0191228.ref031]\].

WES for neurogenetics proved to be an effective, cost- and time-saving approach for the molecular diagnosis of this heterogeneous and complex group of patients. It reduces the long time that these patients must wait before getting a diagnosis thereby ending *odysseys* of many years, impacting on their medical management, and optimizing the genetic counseling for these families. Negative WES still remain a challenge, given the complexity of genomic data interpretation and the lack of a thorough knowledge of monogenic disorders.
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